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There is increasing interest in the characterization of normative senescence in humans. 
To assess to what extent aging patterns in humans are unique, comparative data from 
closely related species, such as non-human primates, can be very useful. Here, we 
use data from bonobos and chimpanzees, two closely related species that share a 
common ancestor with humans, to explore physiological markers that are indicative 
of aging processes. Many studies on aging in humans focus on the somatotropic axis, 
consisting of growth hormone (GH), insulin-like growth factors (IGFs), and IGF binding 
proteins (IGFBPs). In humans, IGFBP-3 levels decline steadily with increasing age. We 
used urinary IGFBP-3 levels as an alternative endocrine marker for IGF-I to identify the 
temporal pattern known to be related with age-related changes in cell proliferation, 
growth, and apoptosis. We measured urinary IGFBP-3 levels in samples from 71 bono-
bos and 102 chimpanzees. Focusing on samples from individuals aged 10 years or 
older, we found that urinary IGFBP-3 levels decline in both ape species with increasing 
age. However, in both species, females start with higher urinary IGFBP-3 levels than 
males, experience a steeper decline with increasing age, and converge with male 
levels around the age of 30–35  years. Our measurements of urinary IGFBP-3 levels 
indicate that bonobos and chimpanzees mirror human patterns of age-related decline in 
IGFBP-3 in older individuals (<10 years) of both sexes. Moreover, such as humans, both 
ape species show sex- specific differences in IGFBP-3 levels with females having higher 
levels than males, a result that correlates with sex differences in life expectancy. Using 
changes in urinary IGFBP-3 levels as a proxy for changes in GH and IGF-I levels that 
mark age-related changes in cell proliferation, this approach provides an opportunity 
to investigate trade-offs in life-history strategies in cross-sectional and in longitudinal 
studies, both in captivity and in the wild.
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inTrODUcTiOn
Compared to other non-human primates, human life span is 
longer and longevity increases progressively in all age classes, 
which translates into an overall “aging” of the human population. 
There is an increasing interest in understanding the biological 
phenomenon of advanced life stages, not only in disease etiol-
ogy but also in characterizing normative senescence (1, 2). 
Senescence describes the time from full maturity to death and is 
characterized by a decline of the integrity and function of organic 
systems, decreased reproduction, and increased mortality (2, 3). 
Ethical and practical issues constrain investigations of such topics 
in humans to some degree, and data from non-human primates 
are considered to offer a good alternative model.
Non-human primates have relatively long life expectancies 
and in most species, individuals experience a phase of life that is 
characterized by visible signs of senescence (4). Additionally, the 
time period during which apparently healthy individuals develop 
alterations in behavior and age-related dysfunctions is longer in 
non-human primates compared to other animals (2). These two 
factors make non-human primates particularly interesting for 
exploring phenotypic traits of human senescence in an evolution-
ary context.
Like humans, many non-human primate species show 
consistent sex differences in aging, with adult males having 
shorter life spans and higher age-specific mortality than adult 
females (5–7). In captive and wild chimpanzees, females have 
on average a longer life span than males [e.g., Ref. (8–10)]. 
In wild bonobos, life expectancy and maximum life span are 
not yet well known, but life expectancy in captivity tends to 
be longer in females than in males (8, 11). The reasons for 
the observed sex differences in life expectancy remain to be 
explored. However, evidence from studies suggests that sex 
differences in life expectancy may be due to health status and/
or behavioral strategies (9, 12, 13). Another possible explanation 
is that the sexes may differ in terms of age-related variation of 
physiological constitution. The goal of our study is to establish 
an endocrine marker to investigate aging processes in bonobos 
and chimpanzees.
Many studies on senescence in humans focused on the soma-
totropic axis, a multicomponent network consisting of growth 
hormone (GH), insulin-like growth factors (IGFs), IGF binding 
proteins (IGFBPs), and IGF receptors and IGFBP proteases 
(BP-Pr). The components of the somatotropic axis are involved 
in the regulation of metabolism and somatic growth, as well as 
proliferation, survival, differentiation, and motility of cells by 
activating multiple signaling pathways [e.g., Ref. (14–16)].
Growth hormone stimulates cell proliferation and regenera-
tion and is a major endocrine regulator of postnatal growth in 
mammals (17). Secretion of GH is regulated by negative feedback 
of serum glucose, free fatty acids, and IGF-I (18, 19).
IGF binding proteins are part of the IGF family of growth 
factors [e.g., Ref. (20, 21)]. In humans and non-human primates, 
IGFs exist in two forms, IGF-I and IGF-II (15). Both are syn-
thesized mainly in the liver, and IGF-I increases in response to 
GH [e.g., Ref. (22, 23)]. In turn, rising IGF-I levels feedback on 
the hypothalamus and pituitary and inhibit GH release (24–26). 
The secretion of IGF-I is GH dependent (25–27) and, therefore, 
can serve as a surrogate marker for anabolic GH activity.
In vitro studies and animal experiments showed synergistic 
actions of GH and IGF-I on carbohydrate and lipid metabolism 
[e.g., Ref. (25, 28, 29)]. In addition, IGF-I is antiapoptotic and 
stimulates cell mitogenesis, survival, differentiation, and somatic 
growth [e.g., Ref. (14, 15, 23)]. Furthermore, IGF-I acts synergis-
tically with insulin in the postprandial period as a hypoglycemic 
hormone (15). The amount of circulating IGF-I is determined by 
its production rate and metabolic clearance, and is modulated 
by IGFBPs that limit the availability of IGF to the IGF receptor 
(23). About 1% of blood IGF-I circulates in its free, unbound 
form, whereas most circulating IGF-I (about 99%) is bound to 
IGFBPs (30).
In humans, six IGFBPs have been identified and constitute an 
elaborate transport and regulatory system for IGF-I, and IGF-I-
independent actions [e.g., Ref. (31)]. The main carrier for IGF in 
serum is IGFBP-3. It constitutes over 95% of the total IGFBP on 
a molar basis in humans (16, 27). IGFBP-3 is synthesized mainly 
in the liver (16, 28, 32). Approximately 80% of IGF-I is bound to 
IGFBP-3, which then forms a large molecular weight complex 
with an acid-labile subunit (ALS) [e.g., Ref. (17, 33)]. While the 
half-life of unbound IGFBP-3 is between 30 and 90  min and 
that of free IGF-I is less than 10 min, the half-life of the complex 
is about 12  h (15). By extending the serum half-life of IGF-I, 
IGFBP-3 affects cellular growth and the availability of IGF to 
receptors (23, 25, 34). Besides these functions, the complex may 
serve as an intravascular reservoir of IGFs that has the potential to 
strengthen or inhibit the activity of IGFs [e.g., Ref. (28, 34–36)]. 
In addition to the modulatory effect on IGF, IGFBP-3 induces cell 
apoptosis and inhibition of proliferation [e.g., Ref. (14, 23, 37)].
In humans, the somatotropic axis is age dependent (22). Serum 
IGF-I levels are low in infancy and childhood, then peak during 
adolescence, and decrease gradually with increasing age [e.g., Ref. 
(16, 36, 38, 39)]. IGFBP-3 levels undergo similar changes: values 
are low at birth, increase rapidly during the first weeks of life, and 
more slowly during later stages until they reach their maxima 
during puberty. From 18 years onward circulating IGFBP-3 levels 
decline steadily [e.g., Ref. (15, 33, 36, 40)]. In adults of both sexes, 
blood IGF-I levels decrease with age (24), and thereby contribute 
to age-related pathogenesis (41). Apart from age-related changes, 
various studies have reported sex-specific differences in IGF-I 
and IGFBP-3 levels: while average IGF-I and IGFBP-3 levels in 
elderly humans did not differ (20), IGFBP-3 levels were signifi-
cantly higher in girls than in boys (38).
From neonates to the elderly, the components of the somato-
tropic axis are critical for survival [e.g., Ref. (42)]. A reduction 
in GH secretion in combination with reduced production of 
IGF-I contributes to an increase in fat mass and a decrease 
in muscle tissue (43). A reduction in IGF-I activity is associ-
ated with morbidity, increasing risk to develop cardiovascular 
disease, osteoporosis, and diabetes (29). Other studies have 
proposed a link between high IGF-I levels and the risk of cancer 
[e.g., Ref. (44)]. The correlation of age-related changes of IGF-I 
and IGFBP-3 levels may be due to a decline in GH secretion 
(43), indicating a causal relationship of the activity of the three 
components (22).
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The age-related changes associated with an increase of 
IGF-I levels during puberty in humans have also been found 
in non-human primates, such as macaques (45–47), baboons 
(48–50), mandrills (51), gibbons (52), and chimpanzees (53). 
As in humans, IGFBP-3 values of rhesus macaques and baboons 
reached their maxima during puberty [e.g., Ref. (45, 48, 54)]. 
Examining IGF-I levels in adult macaques and baboons showed 
that in both species, serum IGF-I levels decreased with age (55, 
56), which is comparable with the human aging pattern.
In non-human primates, adult serum IGF-I levels of males 
were 30% higher than in females in baboons (55), but other stud-
ies did not detect such differences in baboons and mangabeys (54, 
57). IGF-I levels are higher in young female chimpanzees than in 
males (53), whereas in baboons and mandrills the opposite was 
shown (49, 51).
Most studies investigating physiological aging patterns in 
chimpanzees (58, 59) focused on topics, such as reproductive 
senescence (60) and age-related changes of neural structures 
[e.g., Ref. (61, 62)]. Moreover, to our knowledge, no study has 
explored senescence in bonobos, the sister species of chimpan-
zees. Therefore, the aim of the present study is to use measure-
ments of urinary IGFBP-3 levels from captive adult bonobos and 
chimpanzees of both sexes to address the following questions: (1) 
Do urinary IGFBP-3 levels of adult chimpanzees and bonobos 
gradually decline with age? (2) Do females and males in either 
species differ in their overall levels of urinary IGFBP-3? (3) Do 
age-related changes in urinary IGFBP-3 levels of bonobos and 
chimpanzees reflect the observed sex difference in life expectancy?
When exploring the impact of the somatotropic axis on devel-
opment, sex, and aging in non-human primates studies used blood 
samples. Given the ethical constraints imposed by guidelines of 
animal welfare, there is a need for alternative approaches, based 
on sample matrices that can be collected non-invasively. Although 
the IGFBP-3 concentration is approximately three times lower in 
urine compared to serum (35, 37, 63), urine IGFBP-3 measures 
can be used as a physiological marker to assess GH-IGFs aging 
patterns in hominoids and other primates. Urinary IGFBP-3 has 
been measured in urine of healthy humans with Western ligand 
blots (35, 64) and with immunoassay [e.g., Ref. (63, 65)]. IGFBP-3 
levels reflect the GH secretory state, they are significantly cor-
related with serum IGF-I levels (27, 45, 66). Using physiological 
markers that can be extracted from non-invasively collected 
samples has several advantages. First, they facilitate monitoring 
age-related changes over time, collection of longitudinal records, 
construction of life-history profiles, and assessment of fitness (57, 
67). Second, the technique can be applied to individuals living in 
natural environments.
MaTerials anD MeThODs
We measured IGFBP-3 levels in urine samples collected at random 
from 71 bonobos (31 males, 40 females) and 102 chimpanzees 
(33 males, 69 females). All samples were collected non-invasively 
from apes housed in zoo facilities (Table S1 in Supplementary 
Material) in accordance with the recommendations of the NIH 
published standards. Details on the sampling protocol as well 
as the transport and storage of samples have been published 
previously (68). In brief, urine samples were collected directly 
from the urine stream or taken off the ground, only when the 
individual could be identified and when contamination with feces 
could be excluded. After, the samples were immediately frozen 
in the zoo, and transported frozen to the Max Planck Institute 
for Evolutionary Anthropology in Leipzig, Germany. In order to 
explore changes in IGFBP-3 levels during advanced life stages, we 
focused our analyses on individuals of 10 years or older (bonobo 
age range: 10–55 years, average: 23 years; chimpanzee age range: 
10–49 years, average: 23 years). For 54 of the 71 captive bonobos 
the exact birthdate was available from the studbook. For the 
chimpanzees, exact birthdates were available for 81 individuals. 
For six chimpanzees, only the year and month were known, and 
for these we set the day of birth to the 15th of the respective 
month. For the remaining individuals, only the year of birth was 
known, and in these cases the day of birth was set to June 15th of 
the respective year (12 females and 5 males bonobos, 13 females 
and 2 males chimpanzees).
Urinary igFBP-3 analyses
Urinary IGFBP-3 concentrations were measured by a radioim-
munoassay (RIA) developed for human IGFBP-3 detection (40). 
For assay validation, urine samples from bonobos and chimpan-
zees were serially diluted, and dilutions were found to parallel the 
standard curve (Figure S1 in Supplementary Material). Moreover, 
urine samples from each species were spiked with 2.5, 5, and 
10  ng/ml human IGFBP-3, respectively. On average, recovery 
was 111 ± 8%, ranging from 99.0% (2.5 ng/ml spike) to 122.9% 
(5 ng/ml spike). Intra-assay and inter-assay coefficients of vari-
ation were 1.9% and 9.2%, respectively. Based on these results, 
the RIA was considered to be appropriate for measuring IGFBP-3 
concentrations in urine samples of bonobos and chimpanzees.
Urine samples were adjusted for their volume, because the 
concentration of hormones in urine varies with fluid intake 
and the hydration status (69). For chimpanzees, it is suggested 
to correct urine volume using specific gravity (SG) [e.g., Ref. 
(70)]. SG is the ratio of the density of a urine sample relative to 
the density of water. We measured SG with a digital handheld 
refractometer (TEC, Ober-Ramstadt, Germany) and calculated 
urinary IGFBP-3 (nanogram/milliliter) corrected for SG (69, 71). 
The SG population average in our study was 1.007.
statistical analyses
A general linear mixed model [GLMM (72)] was used to explore 
the influence of species, sex, and chronological age on urinary 
IGFBP-3 levels in bonobos and chimpanzees. The model was 
run in R (73) using the function lmer provided in the package 
lme4 (74).
We used a GLMM to investigate the impact of the predictor 
variables, i.e., species, sex, age (chronologic age in years), and sam-
pling time (predictors with fixed effects) on the log-transformed 
response variable: urinary IGFBP-3 levels. The model included 
these four main effects as well as a three-way interaction between 
species, sex, and age, and all two-way interactions between 
them. These interactions were included in the model, because 
we expected that the age-dependent changes of urinary IGFBP-3 
levels may differ between bonobos and chimpanzees and/or 
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between males and females of each species, and that the degree 
of sex differences could be species specific. As a random effect, 
we included location (the zoo housing a specific individual) to 
control for a possible influence of relevant animal husbandry 
conditions of zoos (e.g., diet and group size). Furthermore, we 
included random slopes of age at sampling time within zoo 
to keep type I error rates at the nominal level of 5% (75). Age 
was square root transformed. The transformed age as well as 
the time of sample collection (to control for diurnal variation) 
was z-transformed to a mean of zero and a SD of one to achieve 
comparable estimates (76).
For the model, the required normal distribution and homoge-
neity of residuals were assessed by visual inspections of a histo-
gram, a q–q plot of the residuals, and by plotting residuals against 
fitted values. All model assumptions were met. Model stability 
was tested by excluding zoos one by one, which did not indicate 
any obvious influence of this random effect. To test for collinear-
ity, we examined Variance Inflation Factors [VIF (77)] using the 
function vif of the R-package car (78) applied to a standard linear 
model excluding random effects. These indicated that collinearity 
was not an obvious issue (maximum VIF: 1.044).
Investigating the significance of the fixed effects species, sex, 
age, and all their interactions as a whole (79), we compared the 
full model with a null model, excluding the predictor variables 
and the interactions, but retaining time of sample collection, the 
random effect of zoo, as well as the random slopes component, 
using a likelihood ratio test [Ref. (80); R function “anova”]. The 
data were bootstrapped 1000 times to obtain parameter coef-
ficients. Significance for all tests was set at the P = 0.05 level.
Data for reproductive status were only available for female 
bonobos. To test to what extend female reproductive status 
(cycling, lactating, and pregnant) affect urinary IGFBP-3 levels, 
we used a one-way ANOVA. To achieve normal distribution of 
the response variable, IGFBP-3 levels were log-transformed. This 
analysis was also conducted in R using the function anova.
resUlTs
The full-null model comparison revealed that sex, species, and 
chronologic age had significant effects on urinary IGFBP-3 
levels (χ2 = 35.298, df = 7, P < 0.001). The three-way interac-
tion of sex, species, and chronologic age was not significant 
(estimate = −0.165, SE = 0.235, z-value = −0.703, P = 0.485) 
and was, therefore, excluded from the model. In the reduced 
model, all two-way interactions were included. The interac-
tion of species with age was not significant, because urinary 
IGFBP-3 levels in both species showed a similar decrease with 
age (Figure 1).
All two-way interactions, including species were removed from 
the model. The interaction of chronologic age with sex showed a 
trend (Table 1A). Therefore, we ran a second reduced model with 
the interaction of chronologic age and sex, and species as predic-
tor. The interaction of chronologic age with sex remained a trend 
(Table  1B), demonstrating that age-related changes in urinary 
IGFBP-3 levels differ between the sexes (Figure 2).
To further explore this, we built subsets for each sex and 
ran a second reduced model for each subset without the main 
effect of sex. In both sexes, urinary IGFBP-3 levels decreased 
significantly with chronologic age, but the decreasing slope 
was steeper in females when compared with males (males: esti-
mate = −0.200, SE = 0.082, z-value = −2.433, P = 0.018; females: 
estimate = −0.422, SE = 0.068, z-value = −6.157, P = <0.001) 
(Figure 3). Moreover, urinary IGFBP-3 levels from females started 
from a higher level than samples from males and converged with 
male levels around the age of 30 (Figure 3).
According to this analysis, reproductive status of female 
bonobos did not affect urinary IGFBP-3 levels (F2,37 =  0.219, 
P = 0.804).
DiscUssiOn
Little is known about the process of senescence in chimpanzees 
and to our knowledge nothing has been published about the topic 
for bonobos. However, there is consensus that information on 
aging and senescence from our closest living relatives offers a 
model to better understand the biological components of aging 
and senescence in our own species [e.g., Ref. (1, 5, 81)]. In this 
study, we used urinary IGFBP-3 levels as an alternative endocrine 
marker for IGF-I to identify the temporal pattern known to be 
related with age-related changes in cell proliferation, growth, and 
apoptosis. Focusing on samples from individuals aged 10 years 
or older, we found the following: urinary IGFBP-3 levels decline 
with increasing age. In both species, females start with higher 
urinary IGFBP-3 levels than males, experience a steeper decline 
with increasing age, and converge with male levels around the 
age of 30 years.
The age-related decrease in urinary IGFBP-3 levels obtained 
in our study from chimpanzees and bonobos correspond with 
a significant decline of serum and urinary IGFBP-3 levels with 
increasing age (after mid-puberty) in humans (36, 64, 82, 83). 
Given that a decrease with age in serum IGF-I and IGFBP-3 
levels is consistent with an age-related decline in GH secretion 
in humans (43), we assume that the gradual decline in urinary 
IGFBP-3 levels in the two ape species indicates a corresponding 
change of GH and IGF-I levels. The reduced secretion of GH and 
IGF-I corresponds to the somatopause of humans (20, 84), an 
important determinant in age-related changes in body composi-
tion and function (24, 39, 85).
Our measures of urinary IGFBP-3 levels indicate that bonobos 
and chimpanzees experience an aging pattern in this biomarker, 
similar to that of modern humans, and sex-specific differences 
in IGFBP-3 levels are another trait that the three species share. 
At 10 years of age, female bonobos and chimpanzees have higher 
levels of urinary IFGBP-3 and converge with males at 30 years 
of age. The same sex difference has been reported from several 
human studies, where average serum IGFBP-3 levels were sig-
nificantly higher in women than in men [e.g., Ref. (36, 82, 83, 
86, 87)]. Data for a quantitative comparison between humans, 
bonobos, and chimpanzees are not yet available. First, most 
data from humans are based on serum samples, while our data 
are from urine samples. Second, species-differences in life time 
expectancy complicate direct comparison of hormone levels. 
Third, laboratory methods for measuring IGFBP-3 levels vary 
across studies.
FigUre 1 | Measures of urinary igFBP-3 levels corrected for specific gravity (corr. sg) from bonobos (upper plot) and chimpanzees (lower plot) in 
relation to chronologic age. Sample sizes: Nbonobos = 71 (31 males, 40 females), Nchimpanzees = 102 (33 males, 69 females).
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Previous studies have suggested that the decrease in IGFBP-3/
IGF-I levels may indicate progressive senescence in hominids 
(29). As studies of humans have shown, our study of bonobos 
and chimpanzees found that the sex-specific decline of IFGBP-3 
levels correlates with sex differences in life expectancy. In western 
human societies, women live on average 5–7 years longer (10% 
more) than men (2). In captive apes, females accounted for the 
majority of individuals older than 40  years. This indicates a 
greater survivorship in females than males, and resembles the 
female-biased life expectancy in modern humans (88, 89).
The significantly higher IGFBP-3 levels in elderly women 
correspond with lower bioavailable IGF-I levels, whereas in 
men, the opposite is the case (82, 83, 86, 87). Therefore, one can 
speculate that the higher IGFBP-3 levels found in the females 
of our study reflect lower IGF-I levels. High IGF-I levels may 
promote the functioning of individual tissues and organs, but 
have negative pleiotropic effects on longevity as IGF-I is associ-
ated with increased oxidative damage and risk of pathology 
[e.g., Ref. (41, 90)]. In chimpanzees, kidney and liver function 
decreases significantly with older age. These changes become 
FigUre 2 | Measures of urinary igFBP-3 levels corrected for specific gravity (corr. sg) from female (upper plot) and male (lower plot) bonobos (open 
triangles) and chimpanzees (filled triangles) in relation to chronologic age. The y-axis is displayed on a log scale. Sample sizes: Nbonobos = 71 (31 males, 40 
females), Nchimpanzees = 102 (33 males, 69 females).
TaBle 1 | results of the two reduced general linear mixed models obtained by analyzing urinary igFBP-3 levels from chimpanzees and bonobos of both 
sexes: (a) with species, chronologic age, and sex in interactions; and (B) with the interaction of sex and chronologic age, and species as fixed effect.
Term estimate se DF χ2 P-value
(a) With species, chronologic age, and sex in interactions
Intercept 1.826 0.129
Time of sample collection −0.040 0.056 1 0.501 0.479
Chronologic age*sex 0.224 0.115 1 3.732 0.053
Chronologic age*species −0.068 0.107 1 0.394 0.530
Sex*species 0.052 0.222 1 0.056 0.813
(B) With the interaction of sex and chronologic age, and species as fixed effect
Intercept 1.8211 0.119
Time of sample collection −0.038 0.056 1 0.457 0.499
Species 0.103 0.134 1 0.582 0.466
Chronologic age*sex 0.223 0.115 1 3.691 0.055
In both models, time of sample collection is a fixed effect and zoo facility is a random effect (*refers to an interaction term and bold numbers indicate significance).
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evident in males around 25–30  years and in females between 
30 and 35  years (59). IGFBP-3 is produced by sinusoidal cells 
(22), and an earlier decrease in liver function in males could be 
possibly related to lower IGFBP-3 levels.
Another explanation for the sex differences in IGFBP-3 
levels could be the relationship between IGFBP-3 and repro-
duction. First, pregnancy and breastfeeding are associated with 
increased IGFBP-3 levels in humans (83, 91, 92) and IGFs are 
synthesized by the placenta during pregnancy (93). However, 
in our study, 50% of the female bonobos (20 individuals) were 
lactating and 17.5% (seven individuals) were pregnant, but their 
urinary IGFBP-3 levels did not differ in comparison to cycling 
females. Unfortunately, the reproductive status of the female 
chimpanzees in our study was not sufficiently documented, 
FigUre 3 | Measures of urinary igFBP-3 levels corrected for specific 
gravity (corr. sg) obtained from female (upper plot) and male (lower 
plot) bonobos and chimpanzees in relation to their chronologic age 
(year). Shaded areas represent bootstrapped 95% confidence intervals for 
expected urinary IGFBP-3 levels. The area of the circles corresponds to the 
number of individuals. The y-axis is displayed on a log scale. Sample sizes: 
Nbonobos = 71 (31 males, 40 females), Nchimpanzees = 102 (33 males, 69 females).
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thereby prohibiting us to include this parameter as a confounding 
factor. Second, IGFs regulate gametogenesis and reproductive 
function (48). In humans and in captive and wild chimpanzees, 
birth rates decline at the beginning of the fourth decade of life 
(94). In  women, reproductive senescence is characterized by 
menopause – a sudden decline in fecundity around 50 years of 
age [e.g., Ref. (81)]. Although female chimpanzees and bonobos 
show a similar decline in fecundity at older ages, it is unclear if 
they experience menopause. However, demographic data from 
wild and captive chimpanzees indicate that females do experi-
ence a post-reproductive period [e.g., Ref. (12, 94, 95)]. In our 
study, only five female bonobos (12.5%) and only eight female 
chimpanzees (11.6%) were older than 40 years.
One limitation of our study is its cross-sectional nature, which 
cannot control for the possible effects of inter-individual varia-
tion in development (28). Another limitation is that interventions 
of management and husbandry are likely to influence hormone 
levels. However, the advantage of research on captive apes is the 
exact knowledge of age of the zoo-born individuals, the majority 
of apes, and their long life expectancy (1, 4).
Growth requires input from both, the thyroid axis and the 
somatotropic axis (96). Thyroid hormones may directly regulate 
circulating IGFBP-3 levels (97, 98). Overall, the age-related 
decline in urinary IGFBP-3 found in this study corresponds with 
urinary total triiodothyronine (TT3) changes reported from 
bonobos and chimpanzees (68). However, the sex difference in 
urinary IGFBP-3 levels observed in both species was not found in 
urinary TT3 levels from chimpanzees. By contrast, bonobos show 
sex differences in both markers, but in opposite directions, with 
females having significantly higher urinary IGFBP-3 and lower 
TT3 levels than males. The implication of the different levels in 
these hormones in males and females on health and longevity 
could be explored in future long-term data sets.
Because IGFBP-3 levels can be measured in urine samples, 
this biomarker can be easily used for larger numbers of individu-
als, thereby overcoming limitations of small sample sizes that are 
characteristic of invasive sampling techniques (57, 99). Moreover, 
it facilitates collection of repeated measures within individuals 
to monitor more accurately the process of senescence, which 
helps to understand the evolutionary theory of it. A central 
concept in the evolutionary theory of senescence is the idea 
that aging results from the investment in different life-history 
trade-offs (100). Therefore, measuring urinary IGFBP-3 levels as 
a proxy for changes in GH and IGF-I levels and, thus, as a gross 
estimate of cell proliferation and aging processes, provides an 
opportunity to investigate trade-offs in life-history strategies in 
cross-sectional as well as in longitudinal studies both in captivity 
and in the wild (90).
cOnclUsiOn
Using a cross-sectional study design, we found that urinary 
IGFBP-3 levels decline with age in adult individuals of two 
closely related ape species, bonobos and chimpanzees. In both 
species, urinary IGFBP-3 levels of females started at a higher 
level and had a steeper age-related decline than in males. 
The age-related and sex-specific changes in urinary IGFBP-3 
levels in bonobos and chimpanzees are similar to the patterns 
observed in modern humans. Moreover, in all three species, 
the sex-specific decline of IFGBP-3 levels is correlated with 
sex differences in lifetime expectancy, but in bonobos and 
chimpanzees, the causal link between lifetime expectancy and 
IGFBP-3 needs to be explored. Urinary IGFBP-3 levels can be 
used as an alternative endocrine marker for IGF-I to identify 
the temporal pattern known to be related with age-related 
changes in cell proliferation, growth, and apoptosis in bonobos 
and chimpanzees.
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